# Vectorious Medical Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vectorious-medical-technologies

- Industry: Software
- Headquarters: Tel Aviv-Yafo, Israel
- Website: www.vectoriousmedtech.com/
- Total disclosed funding: $12M
- Latest round: Series B (Jul 16, 2018)
- Investors on record: 6

## About

Vectorious Medical Technologies Ltd. develops advanced cardiac monitoring solutions, specializing in the V-LAP System, a device designed for continuous measurement of left atrial pressure to assist in heart failure management.Founded in 2011 by co-founders Eyal Orion, and Oren Goldstein, Vectorious Medical Technologies Ltd. operates from Tel Aviv-Yafo, Israel. The company focuses on innovative cardiac monitoring solutions, with its flagship product, the V-LAP System, designed to aid in chronic heart failure management. In September 2025, Edwards Lifesciences Corp, fully acquired Vectorious Medical Technologies Ltd. from Broadview Ventures, Champel Capital, EASME, Fresenius Medical Care Ventures, Global Cardiovascular Innovation Center, Go Capital, and RAD BioMed. Following the transaction, Edwards Lifesciences fully owns the company. The company valued at USD 497 million. Vectorious specializes in innovative cardiac monitoring solutions, primarily focusing on their flagship product, the V-LAP System. This investigational device is implanted in the heart's interatrial septum to continuously measure left atrial pressure (LAP), allowing for real-time data transmission that supports physician-guided, patient self-management of chronic heart failure. The system is designed to empower patients by providing daily insights into their heart health, thereby addressing critical challenges associated with heart failure management. The V-LAP System has garnered interest from healthcare providers looking to enhance patient outcomes through advanced monitoring technology. While the company is based in the European Union, the device targets a global market, catering to clinicians and patients in regions where chronic heart failure is prevalent.Vectorious's revenue model primarily revolves around the provision of their V-LAP System for clinical investigation. The company engages in partnerships with healthcare providers and research institutions, facilitating clinical trials and data collection while focusing on improving heart failure management. Transactions are structured to support the integration of this investigational device into clinical settings, with the potential for future applications in hospitals and outpatient care environments. Revenue generation occurs through collaborative agreements and funding from programs such as the European Union Horizon 2020 initiative. These arrangements position Vectorious to establish a robust framework for clinical adoption and long-term partnerships within the healthcare ecosystem.Following the USD 2.000 mn raised in Series B funding in July 2018, Vectorious aims to enhance its product offerings and expand its market reach. In December 2025, Edwards Lifesciences Corp, fully acquired Vectorious Medical Technologies Ltd. from Broadview Ventures, Champel Capital, EASME, Fresenius Medical Care Ventures, Global Cardiovascular Innovation Center, Go Capital, and RAD BioMed. Financial terms of the transaction were not disclosed. The December 2025 acquisition aims to provide Edwards Lifesciences Corp access to Vectorious Medical Technologies Ltd. and capability for Left Atrial Filling Pressure implantable device.

## Funding rounds

- Series B, Jul 16, 2018, $2M — Fresenius Medical Care Ventures
- Series A, Apr 1, 2018 — Champel Capital
- Series B, Mar 7, 2018, $5.3M — Broadview Ventures, Go Capital
- Series A, Feb 26, 2015, $5M — Global Cardiovascular Innovation Center, RAD BioMed

## Investors

- Global Cardiovascular Innovation Center — Series A
- RAD BioMed (https://capitalatlas.ai/funds/rad-biomed) — Series A
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series B
- Go Capital — Series B
- Champel Capital (https://capitalatlas.ai/funds/champel-capital) — Series A
- Fresenius Medical Care Ventures (https://capitalatlas.ai/funds/fresenius-medical-care-ventures) — Series B